Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model.

Hsieh MH, Ho SC, Yeh KY, Pawlak CR, Chang HM, Ho YJ, Lai TJ, Wu FY.

Pharmacol Biochem Behav. 2012 Jul;102(1):64-71. doi: 10.1016/j.pbb.2012.03.022. Epub 2012 Mar 31.

PMID:
22487770
2.

Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model.

Ho SC, Hsu CC, Pawlak CR, Tikhonova MA, Lai TJ, Amstislavskaya TG, Ho YJ.

Behav Brain Res. 2014 Jul 15;268:177-84. doi: 10.1016/j.bbr.2014.04.022. Epub 2014 Apr 19.

PMID:
24755306
3.

Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model.

Hsieh MH, Gu SL, Ho SC, Pawlak CR, Lin CL, Ho YJ, Lai TJ, Wu FY.

Behav Brain Res. 2012 Apr 1;229(1):41-7. doi: 10.1016/j.bbr.2011.12.035. Epub 2012 Jan 2.

PMID:
22227506
4.

Ceftriaxone prevents and reverses behavioral and neuronal deficits in an MPTP-induced animal model of Parkinson's disease dementia.

Hsu CY, Hung CS, Chang HM, Liao WC, Ho SC, Ho YJ.

Neuropharmacology. 2015 Apr;91:43-56. doi: 10.1016/j.neuropharm.2014.11.023. Epub 2014 Dec 10.

PMID:
25499022
5.
6.

Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.

Ambrosi G, Armentero MT, Levandis G, Bramanti P, Nappi G, Blandini F.

Brain Res Bull. 2010 Apr 29;82(1-2):29-38. doi: 10.1016/j.brainresbull.2010.01.011. Epub 2010 Jan 25.

PMID:
20100549
7.
9.

Ceftriaxone reverses deficits of behavior and neurogenesis in an MPTP-induced rat model of Parkinson's disease dementia.

Hsieh MH, Meng WY, Liao WC, Weng JC, Li HH, Su HL, Lin CL, Hung CS, Ho YJ.

Brain Res Bull. 2017 Jun;132:129-138. doi: 10.1016/j.brainresbull.2017.05.015. Epub 2017 May 30.

PMID:
28576659
10.

MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.

Morin N, Grégoire L, Morissette M, Desrayaud S, Gomez-Mancilla B, Gasparini F, Di Paolo T.

Neuropharmacology. 2013 Mar;66:355-64. doi: 10.1016/j.neuropharm.2012.07.036. Epub 2012 Jul 31.

PMID:
22884464
11.

Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.

Morin N, Morissette M, Grégoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T.

Neuropharmacology. 2013 Oct;73:216-31. doi: 10.1016/j.neuropharm.2013.05.028. Epub 2013 Jun 10.

PMID:
23756168
12.
13.

Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons.

Chen L, Zhang QJ, Liu J, Wang S, Ali U, Gui ZH, Wang Y.

Brain Res. 2009 Aug 25;1286:192-200. doi: 10.1016/j.brainres.2009.06.040. Epub 2009 Jun 21.

PMID:
19545547
14.

Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.

Fuzzati-Armentero MT, Cerri S, Levandis G, Ambrosi G, Montepeloso E, Antoninetti G, Blandini F, Baqi Y, Müller CE, Volpini R, Costa G, Simola N, Pinna A.

J Neurochem. 2015 Aug;134(4):740-7. doi: 10.1111/jnc.13162. Epub 2015 Jun 4.

15.

Synergistic effects of ceftriaxone and erythropoietin on neuronal and behavioral deficits in an MPTP-induced animal model of Parkinson's disease dementia.

Huang CK, Chang YT, Amstislavskaya TG, Tikhonova MA, Lin CL, Hung CS, Lai TJ, Ho YJ.

Behav Brain Res. 2015 Nov 1;294:198-207. doi: 10.1016/j.bbr.2015.08.011. Epub 2015 Aug 18.

PMID:
26296668
16.

Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats.

Pellegrino D, Cicchetti F, Wang X, Zhu A, Yu M, Saint-Pierre M, Brownell AL.

J Nucl Med. 2007 Jul;48(7):1147-53. Epub 2007 Jun 15.

17.

Measuring attention in a Parkinson's disease rat model using the 5-arm maze test.

Ho SC, Hsu CC, Yu CH, Huang WN, Tikhonova MA, Ho MC, Hung CS, Amstislavskaya TG, Ho YJ.

Physiol Behav. 2014 May 10;130:176-81. doi: 10.1016/j.physbeh.2014.03.017. Epub 2014 Mar 30.

PMID:
24690450
18.

Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease.

Turle-Lorenzo N, Breysse N, Baunez C, Amalric M.

Psychopharmacology (Berl). 2005 Apr;179(1):117-27. Epub 2005 Feb 22.

PMID:
15726332
19.

Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.

Morin N, Jourdain VA, Morissette M, Grégoire L, Di Paolo T.

Neuropharmacology. 2014 Apr;79:688-706. doi: 10.1016/j.neuropharm.2014.01.014. Epub 2014 Jan 20.

PMID:
24456747
20.

Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats.

Alam M, Danysz W, Schmidt WJ, Dekundy A.

Toxicol Appl Pharmacol. 2009 Oct 15;240(2):198-207. doi: 10.1016/j.taap.2009.07.010. Epub 2009 Jul 17.

PMID:
19616571

Supplemental Content

Support Center